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Patients with renal diseases associated with salt-losing tubulopathies categorized as Gitelman and classic form of
Bartter syndrome have undergone genetic screening for possible mutation capture in two different genes: SLC12A3
and CLCNKB. Clinical symptoms of these two diseases may overlap.
Bartter syndrome and Gitelman syndrome are autosomal recessive salt-losing tubulopathies with hypokalemia,
metabolic alkalosis, hyperreninemia, hyperplasia of the juxtaglomerular apparatus, hyperaldosteronism, and, in some
patients, hypomagnesemia.
Here we describe four patients from an inbred family with a novel missense variant in the CLCNKB gene. All of
patients are asymptomatic; yet they have the typical metabolic abnormality of salt losing tubulopathies. One of
those patients had hypomagnesaemia while others not. Clinical and laboratory data of all patients was described.
All 4 patients have a homozygous c.490G > T missense variant in exon 5 of the CLCNKB gene. This variant alters a
glycine into a cysteine on amino acid position 164 of the resulting protein (p.Gly164Cys). The c.490G > T variant is a
novel variant not previously described in other patients nor controls. Polyphen analysis predicts the variation to be
possibly damaging. Analysis of SLC12A3 was normal.
Here in we are describing a novel homozygous c.490G > T missense variation was identified in exon 5 of the
CLCNKB gene was identified in an Emirati patients with a mild manifestation of Bartter - Gitelman syndrome.
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Bartter syndrome (BS) and Gitelman syndrome (GS) are
autosomal recessive disorders with a characteristic set of
metabolic abnormalities (Amirlak and Dawson 2000;
Konrad et al. 2000; Naesens et al. 2004). These include
hypokalemia, metabolic alkalosis, hyperreninemia, hyper-
plasia of the juxtaglomerular apparatus (the source of
renin in the kidney), hyperaldosteronism, and, in some
patients, hypomagnesemia. (Amirlak and Dawson 2000;
Naesens et al. 2004).
The main pathogenesis in BS is the defect of NaCl re-
absorption in the thick ascending limb of Henle's loop
(TALH). (Konrad et al. 2000) Inherited BS can be divided
into five subtypes according to the different disease genes* Correspondence: ashibli@tawamhospital.ae
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in any medium, provided the original work is pinvolved. Antenatal BS type 1 is due to variants in the
SLC12A1 gene, whereas antenatal BS type II is due to vari-
ants in the KCNJ1 encoding the inward rectifying K +
channel (ROMK). Classical Bartter syndrome (type III) is
caused by variants in CLCNKB encoding the kidney-
specific basolateral chloride channel for cBS. Type IV by
variants in BSND encoding the β-subunit of the basolat-
eral chloride channel for aBS (type IV), and type V by
variants in the calcium-sensing receptors for autosomal
dominant hypocalcemia associated with hypokalemia
(Amirlak and Dawson 2000; Vargas et al. 2011) Apr as
shown in Table 1. In the majority of GS patients, DNA
variants are found in the SLC12A3 gene, which encodes
the thiazide- sensitive NaCl co-transporter (NCC). In a
small minority of GS patients, variants in the CLCNKB
gene encoding the chloride channel ClC-Kb have been
identified (Vargas et al. 2011) Apr. Konrad et al. (Konrad
et al. 2000) and (Jeck et al. 2000) reported that variants inan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Genetics and presentation of Bartter and Gitelman syndromes
Disorder Gene affected Gene product Clinical presentation
Bartter syndrome type I SLC12A1 NKCC2 Antenatal Bartter syndrome (Hyperprostaglandin E syndrome)
Bartter syndrome type II KCNJ1 ROMK Antenatal Bartter syndrome
Bartter syndrome type III CLCKB CLC-Kb Hypochloremia., mild hypomagnesemia, FTT in infancy
Bartter syndrome type IVA BSND Barttin (B-subunit of CLC-Ka
and CLC-Kb)
Antenatal Bartter syndrome (Hyperprostaglandin E syndrome)
and sensorineural deafness
Bartter syndrome type IVB CLCNKA and CLCNKB CLC-Ka and CLC-Kb Antenatal Bartter syndrome (Hyperprostaglandin E syndrome)
and sensorineural deafness
Bartter syndrome type V• CaSR gene CaSR Bartter syndrome with hypocalcemia
Gitelman syndrome SLC12A3 NCC (thiazide- sensitive NaCl
co-transporter).
Hypomagnesemia, hypocalcuria, growth retardation
There are six Bartter syndrome subtypes (I, II, III, IV, IVB, and V) corresponding to six genetic defects. NKCC2: furosemide-sensitive sodium-potassium-2 chloride
cotransporter; ROMK: renal outer medullary potassium channel; CLC-Kb: chloride channel Kb; CLC-Ka: chloride channel Ka; CaSR: calcium sensing receptor; NCCT:
thiazide-sensitive sodium-chloride cotransporter. Modified from Seybrerth et al. (Jeck et al. 2004) Jan.
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drome (type III), but also phenotypes that overlap with ei-
ther antenatal Bartter syndrome (Types I-II) or Gitelman
syndrome. In addition, a pharmacology-based classifica-
tion and pharmacotype terminology for SLTs were devel-
oped and introduced in 2008 (Seyberth 2008) Oct. This
classification is based on three major types of salt-losing
tubulopathy can be defined: distal convoluted tubule
dysfunction (thiazide-like DCT disorders) leading to
hypokalemia (currently known as Gitelman or Bartter
syndrome type III), the second more-severe condition of
polyuric loop dysfunction and furosemide-like loop dis-
orders (often referred to as antenatal Bartter or hyper-
prostaglandin E syndrome or BS types I and II), and the
most-severe condition of combined loop and distal con-
voluted tubule dysfunction (antenatal Bartter or hyper-
prostaglandin E syndrome with sensorineural deafness)
or BS type IV. (Jeck et al. 2004 Jan; Seyberth and
Schlingmann 2011) October.
Here in, we described a case series with mild and
heterogeneous phenotype, all had novel mutation in the
CLCNKB gene.
Case reports
The first patient (proband1) was a 14 years old girl was
presented with prolonged hypokalemia after an attack ofTable 2 Clinical features in all patients
Clinical feature Case 1 (index)
Age in years on presentation/follow up 14
Gender Female
Weight centile on presentation/follow up 75th/90th
Height centile on presentation/follow up 50th/75th
History of polyuria and polydipsia Negative
Blood pressure 114/75
Nephrocalcinosis/Nephrolithiasis Negativeacute gastroenteritis. Review of all systems was negative.
There was no significant perinatal history, her birth
history records revealed full-term by normal spontan-
eous delivery and normal birth weight of 3,400 grams
without antenatal polyhydramnios. There was no history
of chronic drug ingestion. She was doing well in school
and had normal actively level, normal hearing and vision.
On presentation her height (160 cm) and body weight
(58 kg) both were around the 50th percentile. Blood pres-
sure was 114/75 mmHg, heart rate 96 beats/min and
respiratory rate 22/min. The remainder of the physical
examination was unremarkable. Family history was nega-
tive for chronic diseases and sudden death.
The data of biochemical studies are shown in Tables 2
and 3. The most striking findings were hypokalemia
(2.4 mmol/l), metabolic alkalosis with arterial PH of 7.49
(7.35-7.45), HCO3 33 mmol/l. (22-28(mmol/L). EKG dis-
closed a sinus rhythm. Abdominal sonography revealed
bilateral normal size kidneys without nephrocalcinosis.
Urinalysis revealed negative protein, glucose, leukocytes,
and red blood cells. Urine Sodium, Potassium and chlor-
ide levels were 199, 62, and 245 mmol/L respectively (all
should be less than 20 mmol/L). Average urinary volume
was about 1600 ml daily. The trans-tubular potassium gra-
dient (TTKG) was 9.6 (normally it should be less than 3








Table 3 Laboratory features of all patients
Laboratory
findings
Case 1 Case 2 Case 3 Case 4 Normal ranges
Sodium 130 138 138 137 135-143 (mmol/L)
Potassium 2.4 2.3 2.7 2.3 3.4-4.5 (mmol/L)
Chloride 89 96 96 89 98-106 (mmol/L)
Bicarbonate 33 31 32 32 22-28 (mmol/L)
Serum
creatinine
44 30 33 31 27-53 (micromol/L)
Blood urea 3.6 4 2.8 3.9 2.9-7.1 (mmol/L)
Magnesium 0.61 0.92 0.71 0.85 0.74-1.03 (mmol/L)
Renin 216.7 NA NA NA 30-40 ng/L (resting)
Aldosterone 324 NA NA NA 115-406 ng/L
PGE2 140 70 74 44 400-620 ng/24
hours
Urine Ca/Cr 0.42 0.55 0.06 NA <0.7 mmol/mmol
Urine Mg/Cr 1.37 0.65 0.28 NA <0.9 mmol/mmol
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respectively, urine Mg was high with Mg/Cr 1.27 mmol/
mmol (normal < 0.9) and the fractional excretion of Mg
(FeMg) was 3.8 (normal < 2). Serum calcium (Ca) levels
were normal, urine Ca/Cr 0.42 mmol/mmol (normal <
0.7). Normal Prostaglandin E2 (PGE2) level (140 ng/
24 hrs). Sweat chloride test was normal.
Family was counseled for the screening of other siblings
for metabolic abnormalities that was found in another sib-
ling (proband 2) with same hypokalemic metabolic alkal-
osis (Tables 1 and 2). Two of their cousins were having
same manifestation (probands 3 and 4) as explained in the
family pedigree (Figure 1). DNA analysis showed genomic
DNA was extracted from the peripheral white blood cells.Affected Male with homozygous c.490G>T mu
Affected Female with homozygous c.490G>T m
Heterozygous (Male and Female) carriers of c.4
Proband
Proband 1 Proband 2 
Figure 1 Family pedigree of the affected patient showing the affecte
parents are cousins and the grand parents were cousins as well. Parents of
carrier state.Sequencing of the entire coding region (exons 2-20) and
all intron-exon boundaries of CLCNB gene was per-
formed. The reference sequence and exon numbering and
according to Gene bank accession number NM_000085.2,
with the A of the ATG start codon on position 1. A homo-
zygous c.490G > T missense variant was identified in exon
5 of the CLCNKB gene. This variant alters a glycine into
cystine on amino acid position 164 of the resulting protein
(p.Gly164Cys). The c.490G > T variant is a novel variant
not previously described in other patients nor controls.
Polyphen analysis predicts the variant to be "possibly dam-
aging". All of 5 patients were homozygous for the same
variant, whereas their parents were heterozygous for
this missense variant. Sequencing of the entire coding
region (exons 1-26) and al interons-exons boundaries of
the SLC12A3 gene. The reference sequence and exon
numbering are according to Genbank accession number
NM_000339 with the A of the ATG start codon on pos-
ition 1 was done and normal results were obtained.
Discussion
Bartter and Gitelman syndromes are genotypic and
phenotypic heterogeneous diseases. Clinical manifest-
ation and laboratory findings might be misleading in
proposing diagnosis and managing appropriate treat-
ment. (Jeck et al. 2000).
Our patients were having the typical metabolic abnor-
malities of BS/GS tubulopathy. Urine Na, K, and Cl were
significantly high, TTKG was high in the presence of
hypokalemia indicateing renal loss. Their parents and
other heterozygous siblings are normal and they don’t
have electrolytes abnormalities.
The main difference in the clinical presentation of
Bartter and Gitelman Syndromes is explained in Table 4.
(Urbanova et al. 2011) The symptoms of Bartter syndrometation
utation
90G>T mutation 
Proband 3 Proband 4
d patient proband 1 and other affected family members. Both
the two families were having the same mutation in a heterozygous
Table 4 Features differentiating Bartter and Gitelman
syndromes
Features Classic Bartter syndrome Gitelman syndrome
Age at onset Childhood (early) Childhood or later
Maternal hydramnios Rare Absent
Polyuria, polydipsia Present Rare
Dehydration Often present Absent
Tetany Rare Present
Growth retardation Present Absent
Urinary calcium Normal or high Low
Nephrocalcinosis Rare Absent
Serum magnesium Occasionally low Low
Urine prostaglandins
(PGE2)
High or normal Normal
Modified from Urbanova et al. (Peters et al. 2002).
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life, but are usually diagnosed in school age children or
even later in adolescence. Patients present with polyuria
and polydipsia initially, and growth retardation later be-
comes evident if no early intervention is done. (Peters
et al. 2002) Patients with BS are usually associated with
high PGE2 production and hypercalciuria. GS usually has
milder presentation with no polyuria and no failure to
thrive and usually presented later in life. (Seyberth and
Schlingmann 2011) October Our patients showed low
PGE2 and low calcium in urine in contrary to patients
with BS as they trend to have high urine PGE2 levels and
hypercalciuria. (Peters et al. 2002; Brochard et al. 2009)
In our patient Gitelman was initially diagnosed based
on the clinical and laboratory findings and so Genetic
analysis for SLC12A3 gene was done and it was normal;
CLCNKB gene showed a novel mutation in the exon 5.
Co-segregation of this missense variant in an inbred
family with 4 affected patients suggest that this variant is
pathogenic.
Clinical symptoms and biochemical markers of GS
and classic form of Bartter syndrome (type III) may
overlap and thus genetic analysis may specify the real
cause of symptoms. (Brochard et al. 2009) Our patient
had hypomagnesaemia which is due to renal loss based
on the high Mg in the urine in the presence of hypo-
magnesaemia and the high FeMg. Mg supplement was
needed for the index patient but not for the others;
however other patients may develop hypomagnesaemia
in the future as transition phenotypes from classical BS
(cBS) to GS have also been described. (Cruz and Castro
2013 Jan).
There is a difference in both clinical and biochemical
expression of CLCNKB mutations in both GS and type III
BS syndromes between patients who share the samemutations suggests. (Briet et al. 2006; Uchida 2000) A
modifier effect from genetic and/or environmental factors
as it has been often reported in other cases of CLCNKB
mutation (Dong Yan et al. 2010; Nozu et al. 2007) Sep and
other human diseases such as polycystic kidney disease
(Fain et al. 2005). However, the genotype–phenotype rela-
tion is variable, and mutations in the CLCNKB gene may
cause overlapping phenotypes of classic/antenatal BS,
cBS/GS, and GS (Cruz and Castro 2013 Jan; Fain et al.
2005; Peters et al. 2002). Several former studies tried to
focus on the correlation between specific DNA muta-
tion and phenotypic clinical outcome. In a study by
Coto, many individuals carrying exactly the same muta-
tion coming from unrelated families did not correlate in
values of ionic composition in blood and urine. Their
clinical symptoms also differed. (Coto et al. 2004) To
date, more than 30 CLCNKB variants have been re-
ported (Pierre Robitaille et al. 2011; Israel et al. 2003;
Fukuyama et al. 2003; Fukuyama et al. 2004; Rodriguez
et al. 2005; Yu et al. 2010; Xiumin et al. 2013 Feb;
Gorgojo et al. 2006; Lee et al. 2012; Toshihiro et al.
2006; Enriquez et al. 2010 Dec; Konrad et al. 2000a) in
patients with classical BS phenotype, atypical BS or
mixed Bartter-Gitelman phenotypes as found in our
patients. Our family shows that even patients and even
siblings with the same DNA variants could present
differences in clinical symptoms, and even mimic a
different syndromes. This was the case in a study by
Zelikovic, where a large Bedouin family sharing CLCNKB
variant presented clinical characteristics specific for
Gitelman syndrome, on the one side of the spectrum, to
classic Bartter syndrome, on the other. (Zelikovic et al.
2003) Therefore, there is an indication for screening the
CLCNKB gene in those patients with the Gitelman
phenotype who do not have variants in the SLC12A3
gene. (Konrad and Weber 2003).
Conclusion
Our findings demonstrate intrafamilial phenotypic hetero-
geneity, namely the presence of Gitelman syndrome and
classic Bartter syndrome phenotypes in kindred’s with
CLCNKB c.490G > T mutation.
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